Skip to main content
. Author manuscript; available in PMC: 2021 Jun 1.
Published in final edited form as: Gastroenterology. 2020 Feb 19;158(8):2195–2207.e6. doi: 10.1053/j.gastro.2020.02.022

Figure 4. VMR to CRD in rats treated with intracolonic infusion of SLIGKV-NH2 orhistamine.

Figure 4.

(A) Visceral hypersensitivity (VH)–AUC to CRD evoked by intracolonic administration of SLIGKV-NH2 (n = 6) was blocked by pretreatment with celecoxib (n = 6, blue) and cromolyn sodium (n = 6, magenta). Results are expressed as mean ± SEM, *P < 0.05 from PBS (control, black, two-way ANOVA followed with Bonferroni post-hoc test. (B) Similarly, VH to CRD evoked by intracolonic administration of histamine (n = 4, red) was blocked by pretreatment with cromolyn sodium (n = 6, magenta) and celecoxib (n = 6, blue). Results are expressed as mean ± SEM, *P < 0.05 from PBS (control, black, two-way ANOVA followed with Bonferroni post-hoc test. (C) Effects of intracolonic administration of SLIGKV-NH2 and histamine in control (C57BL/6) and Ptgs2Y385F mutant mice, n = 6 in each group. Results are expressed as mean ± SEM, *P < 0.05 from VMR observed in C57BL/6 mice in the SLIGKV-NH2–treated group. # P < 0.05 from VMR observed in C5TBL/6 mice in the histamine-treated group. Two-way ANOVA followed with Bonferroni post-hoc test.